Executive Summary: The project introduces a disruptive electrochemical platform designed for the high-precision synthesis and "reprogramming" of complex biomolecules, specifically therapeutic peptides and peptide-nucleic acid (PNA) conjugates. By shifting from traditional chemical activation to programmable electrode arrays, the technology achieves a quantum leap in synthesis efficiency, purity, and environmental sustainability. Technological Problem & Solution: Current Solid-Phase Peptide Synthesis (SPPS) is burdened by the massive use of hazardous coupling reagents and global deprotection chemicals (e.g., piperidine, TFA), leading to high OPEX and significant ecological footprints. Our solution utilizes an automated electrochemical interface where deprotection and coupling steps are controlled by site-specific electrical potentials. This "Electrochemical Reprogramming" allows for the synthesis of non-standard sequences and post-translational modifications that are notoriously difficult to produce via standard chemical methods. Core Technical Advantages: Precision Control: Real-time feedback loops via electrode impedance spectroscopy ensure 99%+ coupling efficiency per monomer addition. Green Chemistry: Elimination of up to 45% of traditional chemical activators, significantly reducing waste management costs. Scalability: The architecture is designed for parallel synthesis, moving seamlessly from discovery-scale arrays to industrial-scale electrochemical reactors. Compatibility: Optimized for a wide range of redox-mediators and non-canonical amino acids, enabling the creation of novel peptidomimetics. Intellectual Property & Validation: The underlying technology is protected by a comprehensive set of claims (USPTO/PCT structure) covering the unique electrode geometry, the specific redox-cycling algorithms, and the software-defined synthesis protocols. Experimental data at TRL 4 confirms consistent yields and purity levels exceeding current industry benchmarks for 20+ mer sequences. Market Potential & Commercialization: Targeted at the $40B therapeutic peptide market, this IP-NFT offers a strategic advantage for CDMOs and biotech firms (e.g., Bachem, Lonza, PolyPeptide) seeking to optimize production lines. The tokenized asset includes full technical documentation, IPC-classified patent drafts, and a roadmap for pilot-scale integration. Contact for Technical Due Diligence: Teplov.a.g@gmail.com